Pharma-Bio Serv reports FY2023 revenue $17.0M, net income $1.3M, declares special dividend $0.075/share

Pharma-Bio Serv, Inc.

Revenue of $17.0M, down $2.4M YoY; net income of $1.3M, up $0.3M YoY.
Gross profit margin improved 4.6 percentage points compared to last year.
Special dividend of $0.075/share declared; payable Feb 15, 2024 to holders of record Jan 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pharma-Bio Serv, Inc. reported FY ended October 31, 2023 results: revenue approximately $17.0 million, net income approximately $1.3 million.

Period: FY ended October 31, 2023
Revenue: approximately $17.0 million
Net income: approximately $1.3 million
Result: reported results

Exact text from the filing

Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2023 were approximately $17.0 million, a decrease of approximately $2.4 million when compared to last year. Additionally, net income for the year ended October 31, 2023 was approximately $1.3 million, an improvement of approximately $0.3 million when compared to last year.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Pharma-Bio Serv, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-001022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.